Relapsed Or Refractory Chronic Lymphocytic Leukemia - Genasense(R) New Drug Application Accepted For Review By FDA

... GentaIncorporated (Nasdaq: GNTA) announced that the U.S. Food and DrugAdministration (FDA) has accepted the Company''s New Drug Application (NDA) forGenasense(R) (oblimersen sodium) Injection. The NDA proposes the use ofGenasense plus fludarabine and cyclophosphamide for the treatment of patientswith relapsed or refractory chronic lymphocytic leukemia (CLL)... click link for more info. ...